Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Clostridium difficle infection is the leading cause of hospital acquired infection and
infectious diarrhea in hospitalized patients. Eradication treatment for this infection is the
challenging tasks for clinicians due to treatment resistance developed from new hypervirulent
strains. The recurrence rate of this infection is around 20% and there is high
likelihood(60-70%) of another episode after index recurrence. Given constant challenge new
treatment options are under study. Aim of the study is to evaluate if use of bismuth
subsalicylate (BSS) can decrease the length of stay in patients admitted with Clostridium
difficile infection. Secondarily investigators will also see if there is any impact of BSS in
decrease the recurrence.